TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inverse agonist activity at GPR119 (unknown origin) expressed in HEK293 cells assessed as cAMP level by flash plate assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 84nMAssay Description:Inverse agonist activity at GPR119 (unknown origin) expressed in HEK293 cells assessed as cAMP level by flash plate assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Inverse agonist activity at GPR119 (unknown origin) expressed in HEK293 cells assessed as cAMP level by flash plate assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+3nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.00E+3nMAssay Description:Inhibition of human ERG by patch clamp assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5.30E+3nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 5.80E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 8.00E+3nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of human ERG by patch clamp assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.34E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.57E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human ERG by patch clamp assayMore data for this Ligand-Target Pair
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >1.00E+6nMAssay Description:Displacement of [3H]-Astemizole from human ERGMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 46nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 132nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 21nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 7.90nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 6.5nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 93nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 20nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 66nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 196nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 186nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 9.20nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 9.90nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 22nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 326nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 29nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 6.80nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 4.80nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 13nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 8.5nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 70nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 151nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 37nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 76nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 73nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 761nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 21nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair
TargetGlucose-dependent insulinotropic receptor(Homo sapiens (Human))
Arena Pharmaceuticals
Curated by ChEMBL
Arena Pharmaceuticals
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of human GPR119 activity by homogeneous time resolved fluorescence cyclase (cAMP) assayMore data for this Ligand-Target Pair